 |
20 Diseases |  |
18 Trials |
|
18 Trials |  |
1690 News |  |
| «12...678910111213141516...1920» |
- | Zykadia (ceritinib) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma (clinicaltrials.gov) - Nov 25, 2020
P2, N=33, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2020 --> Aug 2021
- |||| Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda
Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1 Rearranged Non–Small-Cell Lung Cancer @ASCO_pubs https://t.co/xZP1UNYyt7 (Twitter) - Nov 12, 2020
- || Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Review, Journal, PD(L)-1 Biomarker, IO Biomarker: New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives. (Pubmed Central) - Nov 11, 2020
Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2020 --> Aug 2021 Challenges in NSCLC treatment include resistance to 3rd generation TKIs, the high cost of ALK inhibitors, and the need for further research on new drugs.
- || Zykadia (ceritinib) / Novartis, Mekinist (trametinib) / Novartis, BeiGene
Enrollment open: Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (clinicaltrials.gov) - Nov 3, 2020
P1, N=27, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Challenges in NSCLC treatment include resistance to 3rd generation TKIs, the high cost of ALK inhibitors, and the need for further research on new drugs. Suspended --> Recruiting
- [VIRTUAL] Comparative efficacy of first-line ALK-inhibitors in ALK+ lung cancer brain metastases: A network meta-analysis () - Oct 24, 2020 - Abstract #SNO2020SNO_515;
This network meta-analysis is the first to compare and rank approved ALKIs used in treating metastatic ALK+ lung cancer. It indicates that BRG, CER, and ALC are better therapeutic options for patients with ALK-naive ALK+ lung cancer brain metastases when compared to CRZ.
- Zykadia (ceritinib) / Novartis
[VIRTUAL] In Vitro & In Vivo Culture of Patient Derived (PD) CSF-CTCs in Leptomeningeal Disease (LMD) From Melanoma to Identify Novel Treatment Strategies () - Oct 24, 2020 - Abstract #SNO2020SNO_52;
As a proof of concept, we assessed response to Ceritinib (Cer), a non-canonical IGF1R inhibitor) in combination with MEK inhibitor... Though the sample size is small, this is the first report of the successful in vitro & in vivo culture of CSF-CTCs from pts with LMD.
- | Zykadia (ceritinib) / Novartis
Trial completion date: Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis (clinicaltrials.gov) - Oct 19, 2020
P1, N=10, Active, not recruiting, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Though the sample size is small, this is the first report of the successful in vitro & in vivo culture of CSF-CTCs from pts with LMD. Trial completion date: Sep 2020 --> Mar 2021
- || Review, Journal: Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer. (Pubmed Central) - Oct 15, 2020
The central nervous system (CNS) activity of alectinib and brigatinib has allowed for treatment of CNS metastases with TKI therapy. Once resistance inevitably develops, newer therapies such as lorlatinib can be considered.
- OBI-833 / OBI Pharma
[VIRTUAL] A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1395;
P1
Funding: OBI Pharma. Clinical trial identification: NCT02310464.
- Zykadia (ceritinib) / Novartis
[VIRTUAL] Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1390;
Legal entity responsible for the study: West China Hospital, SIchuan Universtiy. Funding: National Science Foundation of China (81700095, 81870034).
- OBI-833 / OBI Pharma
[VIRTUAL] A phase I cohort expansion trial of OBI833 in nonsmall cell lung cancer patients (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1031;
P1
Further development of OBI-833 in EGFR-mutated NSCLC patients to assess the potential benefits of combination therapy of OBI-833 with TKIs is ongoing. OBI Pharma.
- Zykadia (ceritinib) / Novartis
[VIRTUAL] Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALKpositive nonsmall cell lung cancer patients with brain metastases in China (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_1026;
Especially the estimated 12-month EFP of intracranial lesions was improved in patients with prior brain radiotherapy. National Science Foundation of China (81700095, 81870034).
- OBI-833 / OBI Pharma
[VIRTUAL] A phase I cohort expansion trial of OBI833 in nonsmall cell lung cancer patients (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_665;
P1
Further development of OBI-833 in EGFR-mutated NSCLC patients to assess the potential benefits of combination therapy of OBI-833 with TKIs is ongoing. OBI Pharma.
- Zykadia (ceritinib) / Novartis
[VIRTUAL] Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALKpositive nonsmall cell lung cancer patients with brain metastases in China (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_660;
Especially the estimated 12-month EFP of intracranial lesions was improved in patients with prior brain radiotherapy. National Science Foundation of China (81700095, 81870034).
- || Xalkori (crizotinib) / Pfizer
Clinical, Journal: How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. (Pubmed Central) - Oct 7, 2020
A molecular-targeted drug (anaplastic lymphoma kinase inhibitor) was found to be extremely effective as selective therapy for inflammatory myofibroblastic tumor with anaplastic lymphoma kinase translocation. Here, we want to emphasize the continuation of this treatment after achieving a good response until progression or a major side effect.
- Lorbrena (lorlatinib) / Pfizer
[VIRTUAL] An Incremental Effectiveness Analysis of Lorlatinib for the Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer that has Progressed after Another ALK Tyrosine Kinase Inhibitor in Portugal () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_1744;
RESULTS : Treatment with lorlatinib allowed for a gain of 1.87 life years (LYs) or 1.40 quality-adjusted life years (QALYs) in patients whose disease progressed after alectinib or ceritinib and a gain of 1.57 LYs or 1.04 QALYs in patients whose disease progressed after crizotinib and another ALK TKI. Sensitivity analyses showed that the model was robust to parameter variation, except for the extrapolations of OS and ToT for lorlatinib.CONCLUSIONS : Lorlatinib results in increased life expectancy and quality-adjusted life expectancy compared with PBC in previously treated adult patients with ALK-positive NSCLC in the Portuguese setting.
- Zykadia (ceritinib) / Novartis
[VIRTUAL] Budget IMPACT Analysis of Ceritinib for Treatment of ALK Positive Locally Advanced or Metastatic NON-SMALL Cell LUNG Cancer in China () - Oct 3, 2020 - Abstract #ISPOREU2020ISPOR-EU_808;
In the total cost budget impact scenario, given China’s annual reimbursement expenditure was over 2,000 billion CNY in 2019, including ceritinib in the NRDL would potentially increase 1.2 million (0.00006%), 21.4 million (0.00107%), 46.9 million CNY (0.00235%) from 2021 to 2023 respectively, totaling 69.6 million in three years. DSA results indicated that the results were relatively insensitive to most parameters except for LC incidence.CONCLUSIONS : The analysis showed that inclusion of ceritinib in China’s national reimbursement list would result in a modest budget impact over a time horizon of 3 years.
- || Zolinza (vorinostat) / Merck (MSD), Zykadia (ceritinib) / Novartis, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Metastases: PEDS-PLAN: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (clinicaltrials.gov) - Sep 24, 2020
P2, N=500, Recruiting, Sponsor: Giselle SaulnierSholler
DSA results indicated that the results were relatively insensitive to most parameters except for LC incidence.CONCLUSIONS : The analysis showed that inclusion of ceritinib in China’s national reimbursement list would result in a modest budget impact over a time horizon of 3 years. Trial completion date: Sep 2026 --> Sep 2032 | Trial primary completion date: Sep 2025 --> Sep 2027
- | Zykadia (ceritinib) / Novartis
Preclinical, Journal: Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model. (Pubmed Central) - Sep 23, 2020
The compound 11 showed better in vitro activity and in vivo efficacy with good pharmacokinetic profile. In vivo efficacy of compound 11 was better than standard drug ceritinib in NCI-H2228 xenograft mice model.
- | Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Journal: ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer. (Pubmed Central) - Sep 23, 2020
In vivo efficacy of compound 11 was better than standard drug ceritinib in NCI-H2228 xenograft mice model. There is no clear evidence of sensitization to radiation by treating EML4-ALK mutated cells with ALK inhibitors.
- || Alunbrig (brigatinib) / Takeda
Clinical, Journal, Real-World Evidence: Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution. (Pubmed Central) - Sep 21, 2020
Six patients had received alectinib as monotherapy, second-line, or third line before brigatinib; of these, four experienced partial responses and two progressed responses. Brigatinib treatment was well tolerated.
- ||| Zykadia (ceritinib) / Novartis
Clinical: You completely true! Same happens with ceritinib when was compared with chemo in ASCEND 4. The important message is that we have very impressive data for our patients! So exciting and dynamic field! (Twitter) - Sep 19, 2020
- || Lorbrena (lorlatinib) / Pfizer
Clinical, Journal: Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer. (Pubmed Central) - Sep 16, 2020
These include hypocholesteremia, hypertriglyceridemia, edema, cognitive effects, weight gain, and diarrhea. Loratinib will play an increasing role in the management of ALK-rearranged NSCLC with the optimal sequencing of ALKi undergoing further research.
- ||| Zykadia (ceritinib) / Novartis
Trial completion date: ASCEND-4: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 11, 2020
P3, N=376, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Loratinib will play an increasing role in the management of ALK-rearranged NSCLC with the optimal sequencing of ALKi undergoing further research. Trial completion date: Feb 2023 --> Sep 2023
- [VIRTUAL] Approved ALK inhibitors induce cytotoxicity in multiple myeloma by targeting the ER-resident kinase LTK and overcoming resistance to proteasome inhibitors (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_2129;
LTK represents the first druggable target in the biosynthetic part of the proteostasis network in MM cells that can be targeted by FDA-approved ALK inhibitors. LTK inhibition using ALK inhibitors should be experimentally explored to treat MM, and in particular PI-resistant MM, in the clinical setting.
- [VIRTUAL] Approved ALK inhibitors induce cytotoxicity in multiple myeloma by targeting the ER-resident kinase LTK and overcoming resistance to proteasome inhibitors (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1520;
LTK represents the first druggable target in the biosynthetic part of the proteostasis network in MM cells that can be targeted by FDA-approved ALK inhibitors. LTK inhibition using ALK inhibitors should be experimentally explored to treat MM, and in particular PI-resistant MM, in the clinical setting.
- [VIRTUAL] Approved ALK inhibitors induce cytotoxicity in multiple myeloma by targeting the ER-resident kinase LTK and overcoming resistance to proteasome inhibitors (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_726;
LTK represents the first druggable target in the biosynthetic part of the proteostasis network in MM cells that can be targeted by FDA-approved ALK inhibitors. LTK inhibition using ALK inhibitors should be experimentally explored to treat MM, and in particular PI-resistant MM, in the clinical setting.
- | Review, Journal: Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC. (Pubmed Central) - Aug 23, 2020
Several more expensive and time-consuming methods are also available nowadays which have the advantage to detect even rarer uncommon ALK fusion variants and mutations in tumour or blood samples. A review of the evolving testing-treatment landscape is needed to highlight the importance of properly diagnosing and treating this group of patients.
- || Clinical, Review, Journal: Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors. (Pubmed Central) - Aug 22, 2020
The ultimate acquisition of resistance to ALK-inhibitor therapy poses a challenge to ongoing research efforts, in addition to the routine management of these patients in the clinic. This review provides a summary of the clinical development of crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib and highlights current management paradigms, current and evolving clinical information, emerging clinical decision-making and sequencing of therapy in advanced, metastatic, or recurrent ALK-positive NSCLC.
- || Zykadia (ceritinib) / Novartis
Clinical, Journal: Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion. (Pubmed Central) - Aug 19, 2020
This report provides the first published demonstration of a patient with IMT with ROS1 fusion successfully treated using ceritinib. Our study suggests that targeting ROS1 fusions using the small molecule inhibitor shows promise as an effective therapy in patients with IMT carrying this genetic alteration, but this requires further investigation in large clinical trials.
- || Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
Clinical, Journal: Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. (Pubmed Central) - Aug 11, 2020
Our study suggests that targeting ROS1 fusions using the small molecule inhibitor shows promise as an effective therapy in patients with IMT carrying this genetic alteration, but this requires further investigation in large clinical trials. Ceritinib showed higher efficacy associated with a better control of systemic progression compared to crizotinib for the front-line treatment of ALK-positive advanced NSCLCs.
- || Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker: Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors. (Pubmed Central) - Aug 8, 2020
This case supports the importance of both histopathologic assessment and comprehensive genomic profiling in selecting appropriate treatment for patients with refractory, metastatic, ALK oncogene-driven non-small cell lung cancer. Use of symptom-directed radiation in tandem with ALK inhibitors contributed to the disease and symptomatic control and prolonged survival in this patient.
- || Zykadia (ceritinib) / Novartis
Would try ceritinib as well, lowest IC50 in @JustinGainor ‘s @CD_AACR paper. @IbiayiMD @JessicaJLinMD, other ideas? #lcsm (Twitter) - Aug 5, 2020
- |||| Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda
Saturday, August 1st is #WorldLungCancerDay #WLCD2020 Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non–Small-Cell #LungCancer @notahedge @DavidHongMD @ASCO_pubs https://t.co/27lsndZvpj (Twitter) - Aug 1, 2020
- Alunbrig (brigatinib) / Takeda
[VIRTUAL] Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2172;
Legal entity responsible for the study: Groupe Français de Pneumo-Cancérologie. Funding: Takeda.
- Alunbrig (brigatinib) / Takeda
[VIRTUAL] Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2130;
Legal entity responsible for the study: Takeda Pharmaceuticals International AG. Funding: Takeda Pharmaceuticals International AG.
- Zykadia (ceritinib) / Novartis
[VIRTUAL] Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2128;
P1
Funding: Novartis. Clinical trial identification: NCT02299505.
- [VIRTUAL] Real-world treatment patterns and outcomes in patients (pts) with advanced, ALK+ non-small cell lung cancer (NSCLC) in Europe (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2120;
Legal entity responsible for the study: Medimix International. Funding: Medimix International.
- || Zykadia (ceritinib) / Novartis
Trial completion date, Trial primary completion date: Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study (clinicaltrials.gov) - Jul 23, 2020
P4, N=252, Recruiting, Sponsor: Novartis Pharmaceuticals
Funding: Medimix International. Trial completion date: Dec 2021 --> Jan 2023 | Trial primary completion date: Dec 2020 --> Jan 2023
- || Alunbrig (brigatinib) / Takeda
Clinical, Journal, Real-World Evidence: Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). (Pubmed Central) - Jul 22, 2020
Trial completion date: Dec 2021 --> Jan 2023 | Trial primary completion date: Dec 2020 --> Jan 2023 These real-world results confirm the efficacy of brigatinib in a cohort of patients heavily pretreated for ALK-positive advanced NSCLC.
- [VIRTUAL] c-Ros oncogene 1 receptor tyrosine kinase (ROS1) partners identified by next-generation sequencing in Chinese patients with solid tumours (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_472;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- | Journal: Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer. (Pubmed Central) - Jul 21, 2020
Nowadays, several molecules are approved for the treatment of ALK+ NSCLC, either in first or further lines of systemic treatment. Several clinical trials are currently ongoing in order to define a potential role of ALK inhibitors in combination with novel anti-cancer agents, as well as monotherapy in neo- and adjuvant settings.
- ||| Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda
Brigatinib or ceritinib. Same experience with a pt Who developed a pneumonitis with alec. No pulmonary toxicity with ceritinib (Twitter) - Jul 20, 2020
- |||||| Clinical, Next-Generation Sequencing: Had a case of Alk rerranged NSCLC progressed on crizo->Ceritinib->Alectinib- >lorlatinib. NGS revealed AlK rearrangement with BRAF fusion .The response to Lorlatinib + Trametinib was fantabulous .Although one can call this anecdotal (Twitter) - Jul 20, 2020
- | Zykadia (ceritinib) / Novartis
Retrospective data, Journal: Ceritinib-Induced Organizing Pneumonia in Lung Cancer: A Retrospective Analysis. (Pubmed Central) - Jul 17, 2020
OP occurs frequently during ceritinib treatment and must be distinguished from disease progression. OP could be reversible without fatal complications and its occurrence is associated with better survival outcomes.
- || Clinical, PK/PD data, Review, Journal: Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. (Pubmed Central) - Jul 9, 2020
Although the absorption, distribution, and excretion of anaplastic lymphoma kinase inhibitors are regulated by drug transporters, their transporter-mediated pharmacokinetics have not yet been elucidated in detail in patients with non-small-cell lung cancer. Further research to analyze the contribution of drug transporters to the pharmacokinetics of anaplastic lymphoma kinase inhibitors in patients with non-small-cell lung cancer will be helpful for understanding the mechanisms of the inter-individual differences in the pharmacokinetics of anaplastic lymphoma kinase inhibitors.
- | Trial completion date, Trial primary completion date, Metastases: MatchMel: Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (clinicaltrials.gov) - Jul 7, 2020
P2, N=1000, Not yet recruiting, Sponsor: Melanoma Institute Australia
Further research to analyze the contribution of drug transporters to the pharmacokinetics of anaplastic lymphoma kinase inhibitors in patients with non-small-cell lung cancer will be helpful for understanding the mechanisms of the inter-individual differences in the pharmacokinetics of anaplastic lymphoma kinase inhibitors. Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022
- || Zykadia (ceritinib) / Novartis, Mekinist (trametinib) / Novartis, BeiGene
Trial completion date, Trial primary completion date, Metastases: Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jul 7, 2020
P1/2, N=69, Recruiting, Sponsor: University of California, San Francisco
Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022 Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Jun 2021
- || Alunbrig (brigatinib) / Takeda
Trial primary completion date, Metastases: ALTA-2: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (clinicaltrials.gov) - Jul 7, 2020
P2, N=104, Active, not recruiting, Sponsor: Ariad Pharmaceuticals
Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Jun 2021 Trial primary completion date: Jun 2020 --> Sep 2020
- || Alunbrig (brigatinib) / Takeda
Trial completion date, Trial primary completion date, Metastases: A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors (clinicaltrials.gov) - Jul 7, 2020
P=N/A, N=160, Recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Trial primary completion date: Jun 2020 --> Sep 2020 Trial completion date: May 2022 --> Nov 2023 | Trial primary completion date: Apr 2022 --> Oct 2023